Formoterol (Perforomist) for COPD.
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016084:Bronchoconstriction / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000068759:Formoterol Fumarate; D006801:Humans; D009330:Nebulizers and Vaporizers; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D003692:Delayed-Action Preparations; D004983:Ethanolamines; D000068759:Formoterol Fumarate